

Cardiovascular medications and long-term mortality among stroke survivors in the Brazilian Study of Stroke Mortality and Morbidity (EMMA)

NIHR Global Health Research Group on Atrial Fibrillation Management

DOI:
[10.1111/ggi.14429](https://doi.org/10.1111/ggi.14429)

License:
Other (please specify with Rights Statement)

Document Version
Peer reviewed version

Citation for published version (Harvard):
NIHR Global Health Research Group on Atrial Fibrillation Management 2022, 'Cardiovascular medications and long-term mortality among stroke survivors in the Brazilian Study of Stroke Mortality and Morbidity (EMMA)', *Geriatrics & gerontology international*, vol. 22, no. 9, pp. 715-722. <https://doi.org/10.1111/ggi.14429>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley's version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited.

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

1 **Abstract**

2 **Aim:** To investigate the association between medication use and long-term all-cause mortality
3 in a Brazilian stroke cohort. **Methods:** Both ischemic and hemorrhagic stroke were evaluated.
4 Medication use was assessed as: never, only pre-stroke, only post-stroke, and continuous use.
5 We evaluated anti-hypertensives, anti-diabetic, lipid-lowering drugs, anti-platelets, and anti-
6 coagulants. Cox regression models were adjusted for sociodemographic and cardiovascular risk
7 factors. **Results:** Among 1,173 incident stroke cases (median age: 68; 86.8% were ischemic,
8 70% first-ever stroke), medication use was low (Overall: 17.5% pre-stroke, 26.4% post-stroke
9 and 40% were under continuous use). Anti-hypertensives and anti-platelets (aspirin) were the
10 most often continuous cardiovascular medication used, 83.5% and 72%, respectively. While
11 statins (39.7%) and anti-diabetics (31.3%) were the least used. Medication use (pre- post-stroke
12 and continuous use) was associated with a reduction in all-cause mortality risk, particularly
13 among those under continuous use (multivariable hazard ratio, 0.52; 95% CI, 0.46-0.66)
14 compared to never users. Among ischemic stroke patients, this effect was similar (multivariable
15 hazard ratio, 0.52; 95% CI, 0.40-0.68). No significant associations were evident among
16 hemorrhagic stroke. **Conclusions:** The risk of all-cause mortality was reduced by 48% among
17 those with ischemic stroke under continuous use of medications. Secondary prevention should
18 be more emphasized in clinical practice.

19 **Keywords:** Stroke epidemiology, Mortality of stroke, Stroke secondary prevention and
20 medication use.

21
22
23
24
25

1 **Introduction**

2 Stroke is one of the leading causes of morbidity and mortality worldwide.^{1,2} The aging
3 population process is one of the main contributors to the increased burden of stroke which is
4 more impacting in low-middle income countries (LMICs).^{1,2} Indeed, most risk factors for stroke
5 can be managed through adequate cardiovascular prevention medication use such as anti-
6 diabetics, anti-hypertensives, and lipid-lowering medications.^{1,3}

7 For non-fatal outcomes, a combination of anti-thrombotic, statins, and anti-hypertensive
8 drugs is associated with an improvement in post-stroke functionality and a reduction in the risk
9 of recurrent stroke.³⁻⁷ Despite the importance of secondary prevention, suboptimal use of
10 cardiovascular medications after stroke is evident even in settings with good healthcare access
11 ⁸, especially among low socioeconomic populations.

12 Cardiovascular medication use, such as statin use, is also associated with better survival
13 after stroke among adults and elderly.^{6,9,10} Combined therapy (anti-hypertensives, statins, and
14 anti-platelet medication) is even more effective in reducing post-stroke mortality.¹¹

15 Prior publications describing cardiovascular medication use and mortality have focused
16 on pharmacotherapy in wealthier countries.^{6,9-12} Information about cardiovascular medication
17 use and mortality particularly in LMICs, in which secondary prevention is a serious issue faced
18 by the public health system, is lacking. Therefore, in this ancillary study from the Study of
19 Stroke Mortality and Morbidity (EMMA), we aimed to investigate the impact of cardiovascular

1 prevention drug therapies on long-term mortality among a low socioeconomic status population
2 afflicted by stroke.

3 **Materials and Methods**

4 *Study design and population*

5 Study subjects are participants in the Study of Stroke Mortality and Morbidity (EMMA
6 study), a well-characterized, long-term stroke surveillance cohort, ongoing since 2006. The
7 EMMA study was based on a Stepwise Approach to Stroke Surveillance (STEPS Stroke-World
8 Health Organization.^{13,14} All patients older than 18 years (median age: 68) with symptoms of
9 acute stroke admitted to one single-center, the Emergency Department (ED) of the HU-USP
10 (University Hospital of the University of Sao Paulo, Brazil), were invited to participate in the
11 hospital phase of the EMMA study.¹⁵ The HU-USP is a secondary community hospital located
12 in a low-income area of approximately 500,000 inhabitants, on the west side of São Paulo city.
13 Of note, all potential candidates for reperfusion therapies are regularly transferred to our referral
14 center and, thus, they were not included in these analyses. Further information about the EMMA
15 study has been published elsewhere.¹⁵

16 Written informed consent was obtained from all EMMA participants or from their
17 advocate (usually a close family member). The study was approved by the local Ethical
18 Committee.

19

20 *EMMA data collection*

21 All data were collected by trained interviewers at hospital admission, at 1-month and 6-
22 months, according to the World Health Organization (WHO) STEPS Manual.^{13,14} As an
23 extension of WHO STEPS stroke, we evaluated EMMA participants yearly or until death up to
24 12 years of follow-up from the baseline of the EMMA study. All losses prior to 12 years were

1 censored at the last date on which they were contacted or when information about their vital
2 status (alive) was confirmed by telephone contact or electronic hospital registers. Mortality data
3 were confirmed by official death certificates in collaboration with the city of São Paulo’s health
4 statistics system (PRO-AIM, Program for Improvement of Mortality Information in the
5 Municipality of São Paulo), State Health Offices (SEADE Foundation, São Paulo State
6 Healthcare Data Analysis System) and the Brazilian Ministry of Health. All information
7 gathered during the follow-up of the EMMA study is updated yearly.

8

9 *Stroke definition*

10 Stroke was defined according to WHO criteria as “a focal (or at times global)
11 neurological impairment of sudden onset, lasting more than 24 hours (or leading to death), and
12 of presumed vascular origin. This clinical definition has, therefore, four components: (1) A
13 neurological impairment or deficit, (2) Sudden onset, (3) Lasting more than 24 hours (or leading
14 to death), and (4) Of presumed vascular origin”¹³, and all of them should be presented for
15 inclusion as a stroke case in the EMMA study. Furthermore, stroke diagnosis was classified
16 according to the International Classification of Diseases, 10th Edition (ICD-10: I60-I63.9).
17 Here, we analyzed individuals with the main subtypes of stroke: IS (I63.X) and HS (I61.X).

18

19 *Socio-demographic, clinical and pharmacotherapy data*

20 Socio-demographic information (age, education, marital status, and race as self-reported
21 skin color: white, mixed, black, and yellow), stroke characteristics (stroke subtype and
22 recurrence), pre-existing cerebrovascular risk factors (CVRF) such as smoking, alcohol
23 consumption and co-morbidities such as hypertension, diabetes mellitus, dyslipidemia, heart
24 failure, and coronary heart disease, atrial fibrillation (AF), chronic obstructive pulmonary

1 disease, dementia, and chronic kidney disease were evaluated at hospital admission and during
2 the follow-up. All information about clinical co-morbidities (prior to index event) and
3 cardiovascular medication were validated by two senior medical researchers, based on medical
4 registries. We considered all clinical diagnoses based on medical history and/or use of
5 medications. Diagnosis of AF at baseline was defined by ECG tracings (before or at hospital
6 admission). Data on medication use such as anti-hypertensive, lipid-lowering, anti-diabetic,
7 anti-platelet, and anti-coagulants were collected at hospital admission (study baseline), 1 month
8 after hospital discharge due to the index event. The degree of functional disability status was
9 evaluated by the modified Rankin Scale (mRS) at 1 month and 6 months after the stroke.
10 Impairment of functionality was categorized from 0 to 2 (mild or independent), from 3 to 5
11 points (moderate-severe or dependent), and 6 points corresponded to death after stroke.

12

13 *Statistical analysis*

14 Categorical variables were analyzed by the Chi-square test and presented as absolute
15 and relative frequencies. As continuous variables had non-parametric distribution, they were
16 analyzed by the Kruskal-Wallis test and presented as median values with respective
17 interquartile range (IQR). Sociodemographic, clinical, and medication for clinical chronic
18 conditions (anti-hypertensive, anti-diabetic, lipid-lowering medication, anti-platelet, and anti-
19 coagulants) variables were analyzed according to cardiovascular medication use based on their
20 previous clinical conditions such as hypertension, dyslipidemia, diabetes atrial fibrillation and
21 coronary artery disease (never used: never used any medication pre- or post-stroke, pre-stroke:
22 medication discontinued post-stroke, post-stroke: medication initiated post-stroke, continuous

1 use: medication used pre-and post-stroke). The long-term mortality risk up to 12 years of
2 follow-up was also evaluated according to cardiovascular medication use.

3 For all-cause mortality up to 12 years of follow-up after an incident event, Kaplan-Meier
4 survival curves were computed and Cox regression models were fitted to calculate hazard ratios
5 (HR) with respective 95% confidence intervals (CI).^{16,17} Regression models are presented as
6 crude (Model 1), age and sex-adjusted (Model 2), further adjusted by education attainment,
7 marital status, hypertension, diabetes, dyslipidemia, smoking, stroke subtype e recurrent stroke
8 (at baseline) (Model 3). Additionally, stratified sensitivity analysis by stroke subtype was
9 performed.

10 Statistical analyses were performed with the statistical software SPSS version 27.0, and
11 for all analyses, p-values less than 0.05 were considered significant.

12 **Results**

13 Between April 2006 and September 2014, 1,863 participants admitted in the ED, and
14 identified as suspected acute stroke were included in the EMMA study. Of these, we first
15 identified 1,183 ischemic strokes (IS; I63.X), 196 hemorrhagic strokes (HS; I61.X), 36
16 unspecified strokes (I64), 160 stroke sequelae (I69.X), 128 transitory ischemic attack (TIA,
17 G45.X), 17 subarachnoid hemorrhage (I60), 25 (I67.X) with other cerebrovascular diseases,
18 118 with other non-neurological diagnoses such as hypoglycemic crisis and two had missing
19 information on clinical data or imaging to confirm or exclude a stroke diagnosis. From 1,379
20 IS and HS, we excluded 40 participants with missing information on medication at baseline or
21 at hospital discharge and 165 who died before the follow-up (1-month after stroke) to update
22 medication for clinical chronic conditions. Thus, the final sample was composed by 1,173
23 participants, 1,018 with IS (86.8%) and 155 with HS (13.2%), who had full information about

1 medication use at baseline (before the stroke) and after hospital discharge (1-month after
2 stroke).

3 *Stroke pharmacotherapy*

4 The main characteristics of the cohort according to the use of medications for clinical
5 chronic conditions are shown in Table 1. Of 1,173 stroke participants (median age 68 years,
6 55.6 % male and 18.8% of illiterates), 86.8% were ischemic, and 70% had a first-ever stroke.
7 Regarding medication use, we noticed an overall low use. The use of medication for chronic
8 clinical conditions was: 17.5% pre-stroke, 26.4% post-stroke, and 40% under continuous use.
9 No patients without main cardiovascular conditions (hypertension, heart failure, dyslipidemia,
10 diabetes) used anti-hypertensive, anti-diabetic, lipid-lowering medications. Overall, patients
11 who never used or discontinued cardiovascular medication after stroke were younger, widowed,
12 had IS and the index event was not a first-time stroke. Also, those reporting never using
13 cardiovascular medications had the lowest frequency of co-morbidities. The percentage of men
14 taking continuous medication was slightly higher compared to women (52.2% vs. 47.8%,
15 $p<0.0001$). White and married participants reported a higher frequency of continuous use of
16 medications for chronic co-morbidities. While educational status did not modify the use of
17 medications, there was lower medication use (19%) in illiterate individuals. Among clinical
18 characteristics, the use of continuous medications was the greatest among individuals with ≥ 3
19 co-morbidities (68.1%). Once again, we observed higher frequencies of main cerebrovascular
20 risk factors in the subgroup under continuous use of cardiovascular medication compared to
21 other subgroups.

22 Detailed information about pharmacotherapy during the follow-up is described in
23 Supplementary Table 1. Overall, cardiovascular medication use was low in the EMMA cohort.
24 The most frequent medication class used in pre-stroke and continuous use groups were anti-

1 hypertensives followed by anti-platelets, lipid-lowering drugs, anti-diabetics, and finally anti-
2 coagulants. From the baseline status (pre-stroke) to one month after stroke, we observed an
3 increase in the use of aspirin (32.4% to 49.4%), statins (16.6% to 25.8%), and OAC (4.9% to
4 9.4%), but not anti-hypertensives and anti-diabetic medications.

5 Among those under continuous use, we observed 83.5%, 72%, 39.7%, 31.3%, 13.4% of
6 the use of anti-hypertensive, aspirin, statin, anti-diabetics, and OAC (mainly VKAs). The
7 exclusion of hemorrhagic stroke did not modify our findings. Of note, all who were taking OAC
8 had an ischemic stroke. Even among those with AF-related stroke (n=155/1,1173, 13.2%), the
9 use of OAC was extremely low pre- and post-stroke, 3.1% and 9.3%, respectively. The use of
10 aspirin was also low in this subset (26.2% pre-stroke and 48.8% post-stroke).

11 The Figure 1 shows a progressively higher degree of functional independence (0-2 points in
12 the modified Rankin scale, mRS) as well, lower proportions of deaths, were observed among
13 patients across the subgroups of cardiovascular medication use, particularly six-month after
14 stroke. Supplementary Table 2 shows the other clinical outcomes for stroke patients during
15 follow-up. Post-stroke (156, 51.3%) and under continuous use of medication (216, 45.6%) had
16 higher access to rehabilitation compared to never use (68, 39.3%) and pre-stroke (60, 30.6%)
17 subgroups, $p < 0.0001$.

18 *Survival and mortality rates*

19 The overall survival rate was 50.4% (591 survivors / 1,173 total sample), which
20 corresponded to a median lifetime of 5.7 years. The number of deaths over the 12-year follow-
21 up was 582. Figures 2 and 3 show survival rates (IS and HS) up to 12 years according to
22 cardiovascular medication use. Ischemic stroke patients who used medications for chronic
23 conditions (anti-hypertensive, lipid-lowering, anti-diabetic, anti-platelet, and anti-coagulants)
24 post-stroke or were under continuous use had better survival rates than those who use only pre-

1 stroke medications or those who never used them (Overall p-Log-rank < 0.0001). These
2 associations were not significant for HS (Overall p-Log rank=0.26).

3 Table 2 shows that overall, using medication at any time (pre- post-stroke and
4 continuous use) was associated with lower all-cause mortality risk, particularly among those
5 under continuous use (all-cause mortality HR, 0.52; 95% CI, 0.40-0.66) compared to never
6 users. Among IS patients, this effect was similar (all-cause mortality HR 0.52, 95% CI 0.40-
7 0.68). No significant associations were evident among HS patients. Additional adjustments for
8 other comorbidities such as AF, CHD, HF did not change the directions and significance of our
9 main findings.

10 **Discussion**

11 Despite high rates of cardiovascular risk factors, such as hypertension, diabetes, and
12 dyslipidemia observed in the EMMA cohort, we observed a low use of medications for chronic
13 clinical conditions, mainly cardiovascular risk factors. After an incident stroke, among those
14 who used medications, anti-hypertensives (IECA) and anti-platelets (aspirin) were the most
15 often taken (at least 70% after stroke). Among those with AF-related stroke, the use of OAC
16 (mainly VKA) barely reached 10% one month after a stroke event. The long-term risk of dying
17 was substantially lower for those who reported using medications for chronic clinical conditions
18 at least up to 1-month after stroke compared to those who reported never using those drugs.
19 Our most meaningful finding, it was a reduction of 48% in the risk of all-cause mortality among
20 those afflicted IS under continuous use of medication. The higher frequency of medication use
21 for cardiovascular risk factors among men can be at least partially explained by the higher
22 frequency of comorbidities, except for atrial fibrillation which was more frequent in women
23 than men. In turn, the highest frequency of continuous use of medications among married
24 participants might be a confounder bias for the association between higher use of continuous

1 use and men since the majority of married participants in our sample were men. Meanwhile,
2 the higher frequency of continuous use of medication among those self-reported as White could
3 be associated with more access to health services and medications in the local public facilities,
4 regardless of sex.

5 To our knowledge, this is the first report evaluating the use of multiple medications for
6 main cerebrovascular risk factors and long-term mortality in a stroke cohort performed in a
7 middle-income country, like Brazil. Based on the present data, we highlight the importance of
8 taking actions to increase the use of cardiovascular medication and improve the accessibility of
9 health care services after a stroke event, since we observed low use of multiple cardiovascular
10 medications in a high-risk population.

11 Most studies analyzing medication use and mortality in a stroke secondary prevention
12 scenario have focused on specific drug classes. For example, blood pressure (BP) control with
13 anti-hypertensive drugs reduces drastically the risk of a second event or death.¹⁸ Also, data from
14 a recent systematic review involving 46 randomized clinical trials (10 anti-platelet agents, 6
15 combinations with aspirin, and 4 OACs) revealed anti-platelets improved ischemic stroke or
16 transient ischemic attack outcomes.¹⁹

17 Previous analyses from the EMMA study also revealed an impressive reduction in long-
18 term mortality rates among those with AF stroke under warfarin use longer than six months
19 after the acute event.²⁰ Of note, the main barriers to effective anti-coagulation therapy in low-
20 middle income countries such as Brazil are the still high cost of DOACs and the lack of sites to
21 periodically perform INR control for those AF stroke cases, which impacts morbidity and
22 mortality after a stroke event particularly in the low-income population²¹ as the case of the
23 participants from the EMMA cohort. Statins also provide beneficial effects for long-term

1 survival, as well as, functional outcome.⁶ Randomized trials showed that statins reduce the risk
2 of having a first or recurrent stroke⁷ and long-term mortality.^{22,23}

3 All the evidence mentioned above shows that cardiovascular medication use is crucial
4 in preventing poor outcomes such as stroke recurrence and mortality. However, the long-term
5 use of multiple medications is associated with a decrease in medication adherence.⁴ In fact,
6 most stroke survivors do not take all their medications.²⁴ A large Brazilian cohort study
7 demonstrated an even higher frequency of none medication use for secondary prevention of
8 stroke in a population with more access to health care services⁸ compared to our current study
9 (23.7% vs. 15.2%).

10

11 *Strengths and limitations*

12 The present study has a robust validation process of the stroke cases, which were
13 classified as the main subtypes of stroke (ischemic and hemorrhagic), including a collection of
14 data on all cerebrovascular risk factors and medications (prior to and during follow-up after an
15 index event), entirely supervised by the medical research team.

16 This study has some limitations, most of them related to selection bias. The EMMA
17 cohort is based on data from one single center, a secondary community hospital, without
18 specialized treatment options (eg. thrombolysis/thrombectomy). Although IS cases who have
19 an indication of any acute therapies are usually transferred to our reference (tertiary hospital),
20 we cannot rule out a selection bias from a highly selected segment of stroke patients from the
21 EMMA cohort that limits the external generalization of our data. We did not have full
22 information about the NIH stroke scale or another measure of disability at hospital admission,
23 as well as, information on stroke recurrence was lacking for all participants included in the
24 present study. The small number of HS did not allow us to have sufficient power to analyze

1 cardiovascular medication use and mortality. Further, we did not have sufficient data about
2 chronic medication after one month of stroke and even the reasons that treatments were never
3 initiated or discontinued among stroke patients included in the EMMA study. A potential
4 selection bias is a reason for discontinuing medication use, which could be a marker of disease
5 severity or mortality. In the EMMA participants. In less than 10% of the EMMA cohort, we
6 collected information about medication adherence through a brief questionnaire and, the main
7 reasons for discontinuation were the oblivion of patients and lack of convenience in the
8 schedule of the dosage proposed by the doctor.

9 Further, a small sample of HS cases was a limitation that did not allow us to explore
10 more consistently the relationship between medication use and mortality among this subset of
11 patients.

12 Since this is an observational study, we cannot rule out the possibility of immortal time bias in
13 our analyses.^{25,26}

14 **Conclusions**

15 In the EMMA cohort, cardiovascular medication use was low, however, the continuous
16 use was associated with a significantly better long-term survival after stroke with a reduction
17 in the mortality risk up to 48%, particularly for those with ischemic stroke under continuous
18 use up to 1-month after acute stroke. The use of cardiovascular medication as secondary
19 prevention should be more emphasized in clinical practice.

20

1 **Acknowledgements**

2 Researchers and physicians linked to the EMMA study, Collaborators from PRO-AIM
3 (Program for Improvement of Mortality Information in the Municipality of São Paulo), SEADE
4 Foundation (São Paulo State Healthcare Data Analysis System) and the Brazilian Ministry of
5 Health.

6 **Members of the NIHR Global Health Group on Atrial Fibrillation Management** listed in
7 alphabetical order: Ajini Arasalingam, Abi Beane, Isabela M Benseñor, Peter Brocklehurst, Kar
8 Keung Cheng, Itamar S Santos, Wahbi El-Bouri, Mei Feng, Alessandra C Goulart, Sheila
9 Greenfield, Yutao Guo, Mahesan Guruparan, Gustavo Gusso, Tiffany E Gooden, Rashan
10 Haniffa, Lindsey Humphreys, Kate Jolly, Sue Jowett, Balachandran Kumarendran, Emma
11 Lancashire, Deirdre A Lane, Xuewen Li, Gregory Y.H. Lip (Co-PI), Yan-guang Li, Trudie
12 Lobban, Paulo A Lotufo, Semira Manseki-Holland, David J Moore, Krishnarajah
13 Nirantharakumar, Rodrigo D Olmos, Elisabete Paschoal, Paskaran Pirasanth, Uruthirakumar
14 Powsiga, Carla Romagnolli, Alena Shantsila, Vethanayagam Antony Sheron, Kanesamoorthy
15 Shribavan, Isabelle Szmigin, Kumaran Subaschandren, Rajendra Surenthirakumaran, Meihui
16 Tai, G. Neil Thomas (Co-PI), Ana C Varella, Hao Wang, Jingya Wang, Hui Zhang, Jiaoyue
17 Zhong.

18 **Funding**

19 This study was funded by the Sao Paulo Research Support Foundation of the State of São
20 Paulo (FAPESP) (grant no. 2018/05512-3) and by the NIHR Global Health Research Group
21 on AF (grant no. 17/63/121).

22

23 **Disclosure statement**

- 1 KASS, ACV, RDO, CR, TEG, GNT, ISS, PAL, IMB and ACG: Declare no conflict of
2 interest.
- 3 GYHL: Consultant and speaker for BMS/Pfizer, Boehringer Ingelheim, and Daiichi-Sankyo.
4 No fees are directly received personally.

References

- 5 1. Krishnamurthi RV, Ikeda T, Feigin VL. Global, Regional and Country-Specific
6 Burden of Ischaemic Stroke, Intracerebral Haemorrhage and Subarachnoid Haemorrhage: A
7 Systematic Analysis of the Global Burden of Disease Study 2017. *Neuroepidemiology*.
8 2020;54(2):171-179.
- 9 2. Phan TG, Haseeb A, Beare R, Srikanth V, Thrift AG, Ma H. Googling the Lifetime
10 Risk of Stroke Around the World. *Front Neurol*. 2020; 11:729.
- 11 3. Hill VA, Towfighi A. Modifiable Risk Factors for Stroke and Strategies for Stroke
12 Prevention. *Semin Neurol*. 2017 ;37(3):237-258.
- 13 4. Brown MT, Bussell JK. Medication adherence: WHO cares? In *Mayo clinic*
14 *proceedings*. 2011; 86 (4) :304-B314.
- 15 5. Poudel RS, Thapa L, Shrestha S, et al. Efficacy of Combined Anti-thrombotic, Statins
16 and Anti-Hypertensive Drugs in Acute Ischemic Stroke. *JNMA J Nepal Med Assoc*.
17 2015;53(197):5-11.
- 18 6. Hjalmarsson C, Bokemark L, Manhem K, Mehlig K, Andersson B. The effect of
19 statins on acute and long-term outcome after ischemic stroke in the elderly. *Am J Geriatr*
20 *Pharmacother*. 2012;10(5):313-322.

- 1 7. O'Regan C, Wu P, Arora P, Perri D, Mills EJ. Statin therapy in stroke prevention: a
2 meta-analysis involving 121,000 patients. *Am J Med.* 2008;121(1):24-33.
- 3 8. Abreu FG, Goulart AC, Birck MG, Benseñor IM. Stroke at baseline of the Brazilian
4 Longitudinal Study of Adult Health (ELSA-Brasil): a cross-sectional analysis. *Sao Paulo Med*
5 *J.* 2018 ;136(5):398-406.
- 6 9. van Dongen MME, Aarnio K, Martinez-Majander N, et al. Use of Statins After
7 Ischemic Stroke in Young Adults and Its Association with Long-Term Outcome. *Stroke.*
8 2019;50(12):3385-3392.
- 9 10. Flach C, Elstad M, Muruet W, Wolfe CDA, Rudd AG, Douiri A. The Impact of Pre-
10 and Post-Stroke Statin Use on Stroke Severity and Long-Term Outcomes: A Population-
11 Based Cohort Study. *Cerebrovasc Dis.* 2019;47(5-6):260-267.
- 12 11. Hassan Y, Al-Jabi SW, Aziz NA, Looi I, Zyoud SH. Impact of the additive effect of
13 angiotensin-converting enzyme inhibitors and/or statins with anti-platelet medication on
14 mortality after acute ischaemic stroke. *Basic Clin Pharmacol Toxicol.* 2012;110(4):370-377.
- 15 12. Scheitz JF, MacIsaac RL, Abdul-Rahim AH, et al; VISTA collaboration. Statins and
16 risk of poststroke hemorrhagic complications. *Neurology.* 2016;86(17):1590-1596.
- 17 13. World Health Organization. WHO STEPS stroke manual: the WHO STEPwise
18 approach to stroke surveillance/noncommunicable diseases and mental health. World Health
19 Organization; 2006. [cited 12/06/2010]. Available from: World Health Organization
20 <http://www.who.int/chp/steps/stroke/manual/en/index.html>
- 21 14. Lotufo PA, Benseñor IM. Improving WHO STEPS Stroke in Brazil. *Lancet*
22 *Neurol.* 2007;6(5):387-388.

- 1 15. Goulart AC, Bustos IR, Abe IM, et al. A stepwise approach to stroke surveillance in
2 Brazil: the EMMA (Estudo de Mortalidade e Morbidade do Acidente Vascular Cerebral)
3 study. *Int J Stroke*. 2010;5(4):284-289.
- 4 16. Kaplan EL, Meier P. Nonparametric Estimation from incomplete observations. *J Am*
5 *Stat Assoc*. 1958; 53 (282) :457–481.
- 6 17. Cox DR. Regression model and life tables. Series B (Methodological). *J Royal Stat*
7 *Soc*. 1972; 34:187–220.
- 8 18. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies
9 Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-
10 analysis of individual data for one million adults in 61 prospective studies. *Lancet*.
11 2002;360(9349):1903-1913.
- 12 19. Tornyos D, Bálint A, Kupó P, El Abdallaoui OEA, Komócsi A. Anti-thrombotic
13 Therapy for Secondary Prevention in Patients with Non-Cardioembolic Stroke or Transient
14 Ischemic Attack: A Systematic Review. *Life (Basel)*. 2021;11(5):447.
- 15 20. Goulart AC, Olmos RD, Santos IS, et al. The impact of atrial fibrillation and long-term
16 oral anti-coagulant use on all-cause and cardiovascular mortality: A 12-year evaluation of the
17 prospective Brazilian Study of Stroke Mortality and Morbidity. *Int J Stroke*.
18 2021;1747493021995592.
- 19 21. Santos IS, Goulart AC, Olmos RD, et al; NIHR Global Health Group on Atrial
20 Fibrillation Management. Atrial fibrillation in low- and middle-income countries: a narrative
21 review. *Eur Heart J Suppl*. 2020 ;22(Suppl O): O61-O77.

- 1 22. Dowlatshahi D, Demchuk AM, Fang J, Kapral MK, Sharma M, Smith EE; Registry of
2 the Canadian Stroke Network. Association of statins and statin discontinuation with poor
3 outcome and survival after intracerebral hemorrhage. *Stroke*. 2012;43(6):1518-1523.
- 4 23. Tramacere I, Boncoraglio GB, Banzi R, et al. Comparison of statins for secondary
5 prevention in patients with ischemic stroke or transient ischemic attack: a systematic review
6 and network meta-analysis. *BMC Med*. 2019;17(1):67.
- 7 24. Hornnes N, Larsen K, Boysen G. Blood pressure 1 year after stroke: the need to
8 optimize secondary prevention. *J Stroke Cerebrovasc Dis*. 2011 ;20(1):16-23.
- 9 25. Suissa S. Immortal Time Bias in Pharmacoepidemiology. *American Journal of*
10 *Epidemiology*. 2008; 167 (4): 492–499.
- 11 26. Lévesque LE, Hanley JA, Kezouh A, Suissa S. Problem of immortal time bias in
12 cohort studies: example using statins for preventing progression of diabetes. *BMJ*. 2010
13 ;12(340): b5087.

Figure Legends

Fig. 1. Functional impairment by modified Rankin- scale according to cardiovascular medication use in the EMMA cohort

Fig. 2. Kaplan Meyer survival curve for all-cause mortality according to cardiovascular medication use in ischemic stroke during 12-year follow-up in the EMMA cohort

Fig. 3. Kaplan Meyer survival curve for all-cause mortality according to cardiovascular medication use in hemorrhagic stroke during 12-year follow-up in the EMMA cohort

Supplementary table titles

Table 1. Pharmacotherapy among participants from the EMMA study during the follow-up

Table 2. Clinical conditions after hospital discharge due to stroke (index event) according to cardiovascular medication use in the EMMA cohort